Performance of two frailty screening tools among patients with cancer in Taiwan

Shih-Ying Chen a, Wen-Chi Chou b,c, Yung-Chang Lin b,c, Ngan-Ming Tsang b,d, Kuo-Chen Liao b,e, Chung-Hao Lin b,e, Jr-Rung Lin b,f, Ya-Wen Ho a, Woung-Ru Tang a,g,*

a School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan
b College of Medicine, Chang Gung University, Taoyuan, Taiwan
c Department of Hematology-Oncology and Cancer Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
d Department of Radiation Oncology and Cancer Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
e Department of General Medicine and Geriatric, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
f Clinical Informatics and Medical Statistics Research Center, Graduate Institute of Clinical Medicine, Chang Gung University at Linkou, Taoyuan, Taiwan
g Department of Nephrology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

ABSTRACT

Background: Comprehensive Geriatric Assessment (CGA) is the gold standard for detecting frailty in elderly patients with cancer. Since CGA is time- and resource-consuming, many alternative frailty screening tools have been developed; however, it remains unknown whether these tools are suitable for older and adult patients with cancer. Therefore, we used the data collected for a large longitudinal study to compare the diagnostic performances of two frailty screening tools (Geriatric 8 [G8] and Flemish version of the Triage Risk Screening Tool [fTRST]) to identify frailty risk profile among patients with cancer.

Methods: Patients aged ≥20 years with newly diagnosed cancer were enrolled. Frailty screening with G8, fTRST, and CGA were performed before anti-cancer treatment. Diagnostic characteristics obtained using G8 and fTRST were analyzed by C-index, and the validity of G8 and fTRST was also determined.

Results: 40.9% of the 755 patients with cancer displayed frailty on CGA. Both G8 and fTRST showed high sensitivity (80.6–88.4%) and negative predictive value (81.0–81.2%). The C-index of G8 was higher than that of fTRST (0.77 vs 0.71, p = .01). Moreover, the best G8 and fTRST cut-off points were ≤13 and ≥2, respectively. The validities of G8 and fTRST were also confirmed; however, frailty age differences were not observed in our study.

Conclusion: Frailty is a common problem for patients with cancer, and routine frailty screening is essential for both older and adult patients. G8 and fTRST are simple and useful frailty screening tools, while G8 is more suitable than fTRST for Taiwanese patients with cancer.

* Corresponding author. School of Nursing, College of Medicine, Chang Gung University, 259 Wenhua 1st Rd., Guishan, Taoyuan, Taiwan.
E-mail address: wtang@mail.cgu.edu.tw (W.-R. Tang).
Peer review under responsibility of Chang Gung University.
https://doi.org/10.1016/j.bj.2021.03.002
2319-4170/© 2021 Chang Gung University. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Frailty refers to the decline in reserve capacities of multiple systems (physiology, cognition, nutrition, social support, and psychology), which makes individuals fail to maintain homeostasis in the face of stressors. The early assessment of frailty can serve as a reference for treatment-related decision-making.

Frailty refers to the decline in reserve capacities of multiple systems (physiology, cognition, nutrition, social support, and psychology), which makes individuals fail to maintain homeostasis in the face of stressors [5–8]. Many international academic associations (e.g., National Comprehensive Cancer Network [NCCN] and International Society of Geriatric Oncology [SIOG]) have indicated that the Comprehensive Geriatric Assessment (CGA) is the gold standard for assessing frailty and helps us to objectively understand the health condition of various systems in elderly patients with cancer [9,10]. Our previous study indicated frailty was common in patients with primary head and neck cancer and was independently associated with poor survival, high treatment-related complications, and severe adverse events of concurrent chemoradiotherapy [11]. Nevertheless, it is time- and resource-consuming to perform CGA, and those that assess CGA must receive professional geriatric training as well. Therefore, in order to strengthen the clinical use of frailty indicators, many frailty screening tools have been developed, including Geriatric 8 (G8) [12], Flemish version of the Triage Risk Screening Tool (fTRST) [13], and Abbreviated Comprehensive Geriatric Assessment (aCGA) [14]. Hopefully, clinicians will be able to efficiently use conventional screening tools to assess frailty in the future.

Many studies have compared the diagnostic characteristic of frailty screening tools [8,15–18]. However, screening tool recommendations have been inconsistent. Previous studies on frailty and screening tools have mainly been designed for the elderly population. However, non-elderly populations have also experienced frailty [19,20]. To date, no study has investigated frailty in both elderly and non-elderly patients with various cancer types. Therefore, our study aimed to test the performance and validity of G8 and fTRST for frailty screening in elderly and non-elderly patients with cancer in Taiwan.

**Materials and methods**

**Patient population and data collection**

Our study is part of a large longitudinal study that investigated factors affecting the frailty of patients with cancer in Taiwan and the correlation of these factors with the occurrence of severe complications. Data were collected from three hospitals in Taiwan, with a total of four data collection points. For the purpose of our study, we used only baseline data to investigate the performance of G8 and fTRST in patients with cancer. We used convenience sampling, and the inclusion criteria were as follows: (1) patients ≥20 years of age; (2) outpatients or inpatients who were diagnosed with cancer by clinical physicians and scheduled for high-intensity anticancer treatments within two weeks (radical surgery, adjuvant chemotherapy, or concurrent chemoradiotherapy [CCRT]); (3) patients who are conscious and can communicate in Mandarin or Taiwanese. The exclusion criteria were as follows: (1) patients with cognitive impairments, who are unable to complete the questionnaires; (2) patients who did not receive treatment with a curative purpose (e.g., palliative chemotherapy or radiotherapy) or had distant metastases. Our study was approved by the institutional review board of the study site (No: 1608080002). We obtained informed consent from all patients before the interviews. All patients with cancer completed the frailty questionnaires (G8, fTRST, and CGA) with the assistances of the first author (SY Chen) and a trained research assistant before receiving anti-cancer treatment. The average assessment time was 30 min (2 min for G8, 2 min for fTRST, and 26 min for CGA).

**Frailty screening tools (G8 and fTRST)**

The G8 was developed by Soubeyran et al. [12] and has been used to assess the risk of frailty in elderly patients with cancer [18,21]. This screening tool contains seven items and the total score is 0 (heavily impaired) to 17 (not at all impaired) points. The score ≤14 is considered abnormal and indicates a frailty risk profile [18,21].

The TRST was developed by Meldon et al. and has been used to assess the risk of being unable to be discharged from...
the emergency room [13,22]. The research team of the University Hospitals Leuven partially modified the TRST to the fTRST, which evaluates the frailty risk profile of elderly patients [23]. This screening tool includes a total of five items, and the total score is 0–6 points. Within the oncologic population, the score ≥2 is considered to represent a frailty risk profile [23,24]. Both G8 and fTRST cut-off scores were taken into account in our study.

CGA

CGA is the gold standard tool for assessing frailty in elderly patients [9,10]. Since no comprehensive measurement tool was developed to assess frailty in the non-elderly population, CGA has been chosen to assess frailty in non-elderly population [11]. Therefore, we used CGA as the measurement tool for assessing frailty in both elderly and non-elderly patients in our study. In past studies, CGA mainly included five dimensions. Patients with ≥2 impaired dimensions were considered as patients with frailty [25,26]. Specifically, the CGA was used to define which patients had a frailty risk profile, over five dimensions (functional status, nutrition, comorbidity, mobility/falls, and polypharmacy), and patients who exhibited impairments in ≥2 domains within the CGA were defined as patients with frailty. The assessment tools and cut-off standards of various dimensions are shown in [Table 1].

Statistical analysis

Data analyses were performed using SPSS 22.0 statistical software package (SPSS, Armonk, NY: IBM Corp) and a p-value <0.05 was considered statistically significant. The ROC curve was used to detect diagnostic characteristics of G8 and fTRST. CGA was the comprehensive tool for diagnosing frailty and for comparing the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Youden index [32], and C-index [33] of G8 and fTRST. In general, a C-index ≥0.7 was deemed acceptable for discriminating frailty [34].

Our study used logistic regression and multiple regression to establish the validity of screening tools. Construct validity was used to investigate the effects of ECOG and age on frailty. Previous studies indicated that impaired functional status and elderly always with high level of frailty [35,36], thus we divided ECOG (0 vs ≥1 points) and age (<65 and ≥65 year) into two groups for known groups comparison. The significant variables in the univariate analysis were set as control variables for multiple regression analysis, and we subsequently detected the effects of ECOG and age on frailty.

Results

Analysis of patient demographic and clinical characteristics

Seven hundred and fifty-five patients with cancer were enrolled in our study. The mean age was 63.3 ± 12.2 years, and 418 (55.4%) patients were over the age of 65. Most of the patients were male (71%) and married (75.4%). Head and neck cancer was the most general diagnosis (50.3%), followed by colorectal cancer (20.0%). Moreover, 28.5% of the patients were diagnosed with stage III cancer, and 33.0% of the patients were of stage IV. For ECOG, 59.6% of the patients had a score of 0 point. Most of the patients had chronic comorbidities (59.1%). Relevant demographic and clinical characteristics are shown in [Table 2].

Prevalence of frailty in overall, elderly, and non-elderly patients as per CGA and two other screening tools

A frailty risk profile, determined by CGA, was present in 40.9% of the overall patient population, and 47.6% and 32.6% of the elderly (≥65) and non-elderly (<65) patients, respectively. With respect to the different screening tools, the prevalence of frailty, as determined by G8 (<14), was 57.7% in the patient population, and 55.5% and 60.5% in elderly and non-elderly patients, respectively. The prevalence of frailty, as determined by fTRST (≥1), was 75.0% in the overall patient population, and 78.1% and 71.2% in elderly and non-elderly patients, respectively.

Diagnostic characteristics and C-index of G8 and fTRST

High sensitivities (80.6% and 88.4%) and NPVs (81.2% and 81.0%) were found for both G8 (<14) and fTRST (≥1). However, the C-index of G8 was higher than that of fTRST (0.77 vs 0.71, p = .01). According to the Youden index, our study found that the best cut-off for G8 was ≤13 points (Youden index = 0.404), which had a sensitivity of 68.4% and NPV of 78.6%, and the best cut-off for fTRST was ≥2 points (Youden index = 0.337), which had a sensitivity of 65.5% and NPV of 74.2% [Table 3] and [Fig. 1].

| Table 1 Measures of CGA. |
|---------------------------------|----------------|----------------|----------------|
| Frailty domain                  | Measures       | No items | Score range | Cut-off value |
|---------------------------------|----------------|----------|-------------|---------------|
| Functional status               | Barthel index (ADL) [27] | 10       | 0–100       | ≤100          |
|                                  | Lawton scale (IADL) [28] | 8        | 0–8         | ≥7            |
| Nutrition                       | MNA-SF [29]   | 6        | 0–14        | ≤11           |
| Comorbidity                     | CCI-Q [30]    | 17       | 0–33        | ≥3            |
| Mobility/Falls                  | Number of falls [14] | 1        | 0–∞         | ≥2            |
| Polypharmacy                    | Number of medications [9,31] | 1        | 0–∞         | ≥5            |

Abbreviations: ADL: activities of daily living; CCI-Q: Charlson comorbidity Index-Quan; IADL: instrumental activities of daily living; MNA-SF: mini nutritional assessment-short form.
Validity of G8 and fTRST

Our study used CGA as the comprehensive tool for frailty assessment, and found that both G8 (Wald’s $\chi^2 = 127.80, p < .001$) and fTRST (Wald’s $\chi^2 = 94.22, p < .001$) significantly correlated with CGA, which supports the convergent validity of G8 and fTRST. By using known groups comparison, we found that there were significant differences in G8 ($\Delta R^2 = 0.06, p < .001$) and fTRST ($\Delta R^2 = 0.02, p < .001$) scores among different ECOG scores ($\geq 1$ vs $0$ point). A higher ECOG score (poorer physical activity) indicates a higher frailty [Table 4]; however, age did not have a significant influence on both G8 ($\Delta R^2 = 0.00, p = .999$) and fTRST ($\Delta R^2 = 0.00, p = .397$) scores [Table 5].

Comparison of G8 and fTRST performance between patients with or without head and neck cancer (HNC)

As patients with HNC accounted for more than 50% of our subjects, we divided the entire patient cohort into HNC and non-HNC groups to evaluate the performance of G8 and fTRST. No significant differences were found in the C-index of G8 and fTRST between HNC and non-HNC groups (G8: 0.77 vs. 0.80, $p = 0.41$; fTRST: 0.73 vs. 0.68, $p = 0.23$) (Supplementary Fig. 1 & Fig. 2).

Discussion

Our study investigated the diagnostic characteristics and validities of G8 and fTRST in patients with cancer and compared them to a frailty risk profile according to the CGA. The prevalence of frailty in the patients with cancer who were enrolled in our study was 40.9% (CGA). Handforth et al. [26] reviewed 16 studies of frailty in elderly patients and discovered that the mean prevalence of frailty was 43%, which is similar to that in our study. Apart from the elderly population, our study also enrolled a non-elderly population, to accentuate the fact that frailty is also universal in non-elderly patients with cancer (32.6%) and to remind our readers that clinical frailty assessments should be performed on both elderly and non-elderly patients. Our study is the first to apply G8 and fTRST to both elderly and non-elderly patients with cancer. Previous studies have mainly focused on elderly

| Table 2 Patient demographic and clinical characteristic (N = 755). |
|---------------------------------------------------------------|
| Demographic and clinical characteristic | N   | %    |        |
| Age (mean ± SD)                                               | 63.3 ± 12.2 |
| ≥ 65 y                                                        | 418  | 55.4 | –2.41* |
| <65 y                                                        | 337  | 44.6 | –4.84***|
| Gender                                                       |      |      |        |
| Male                                                         | 536  | 71.0 | –0.29  |
| Female                                                       | 219  | 29.0 | –2.31* |
| Marital status                                               |      |      |        |
| Married                                                      | 569  | 75.4 | 2.40*  |
| Other                                                        | 186  | 24.6 | –2.75**|
| Education                                                    |      |      |        |
| Primary                                                      | 297  | 39.3 | 7.33** |
| Junior/Senior high                                           | 419  | 55.5 | 2.83   |
| College/Master                                               | 39   | 5.2  |        |
| Cancer type                                                  |      |      |        |
| Colorectal                                                   | 151  | 20.0 | 4.96***|
| Head & Neck                                                  | 380  | 50.3 | 4.35***|
| Liver                                                        | 37   | 4.9  |        |
| Breast                                                       | 48   | 6.4  |        |
| Gastric                                                      | 50   | 6.6  |        |
| Non-Hodgkin Lymphoma                                         | 32   | 4.2  |        |
| Other                                                        | 57   | 7.5  |        |
| Cancer stage                                                 |      |      |        |
| Stage I                                                      | 97   | 12.8 | 8.02***|
| Stage II                                                     | 194  | 25.7 | 1.76   |
| Stage III                                                    | 215  | 28.5 |        |
| Stage IV                                                     | 249  | 33.0 |        |
| ECOG Score = 0                                                | 450  | 59.6 | 9.94***|
| Score ≥ 1                                                    | 305  | 40.4 | –4.24***|
| Comorbidity                                                   |      |      |        |
| Yes                                                          | 446  | 59.1 | –0.44  |
| No                                                           | 309  | 40.9 | –5.09***|

*p < .05 **p < .01 ***p < .001.

[Table 4]

[Table 5]
patients with cancer and have rarely investigated frailty in both elderly and non-elderly patients with cancer. Two studies have analyzed frailty in healthy elderly and non-elderly population, and these investigations found that the mean prevalence of frailty was 7.4% [19,20], which is significantly lower than that reported in our study. This difference might be caused by the disease, since the physical status of patients with cancer is weaker than that of generally healthy individuals, and thus, the prevalence of frailty is higher for patients with cancer.

The sensitivity of G8 (≤14) and fTRST (≥1) in our study were 80.6% and 88.4%, respectively. We reviewed previous studies of frailty in elderly patients with cancer and found that the mean sensitivity of G8 and fTRST was 86% [15–18,21,37–39] and 92% [16,23,38], respectively, which are higher than the values that were observed in our study. The high sensitivity can be explained by the fact that G8 and fTRST were developed for elderly patients. Previous studies have also applied these tools to elderly patients (>70 years old) [16–18,21,37], and most of these patients were in advanced stages or received palliative care [16,21,37–39]. In addition, our study excluded patients with cognitive impairment, and there have been no discriminations in cognition-related items in the screening tools that were used for patients in our study. This lessened the sensitivity of our study, in comparison to the results of past studies. Although frailty in both elderly and non-elderly patients with cancer has rarely been assessed in previous studies, our study verified that both G8 and fTRST can effectively screen frailty risk profiles in patients with cancer who are of different ages, and the sensitivity of these tools is not inferior to that observed in prior frailty studies in elderly patient with cancer.

Many past studies have applied G8 and fTRST to clinical practices and have verified that these screening tools are highly sensitive and effective screening tools [15,16,18,21,37,39]. Our study also found that both G8 and fTRST can effectively predict frailty in elderly and non-elderly
patients with cancer (C-index = 0.71–0.77). Although the G8 cut-off point that has been recommended by scholars was ≤14 [18,21], and that of fTRST was ≥1 [16,23,24], our study found that the best cut-off point of G8 for patients with cancer in Taiwan should be decreased to ≤13, and that of fTRST should be increased to ≥2. Such differences may be caused by the fact that the cut-off points that were recommended by past studies were for elderly patients with cancer [16,18,21,23], most of whom were in advanced stages or received palliative care [16,21] and had a high prevalence of frailty (71–83%). Therefore, the prevalence of frailty in our investigation is lower than that in past studies, and the best cut-off point that we recommend based on our study also differs from the recommendations of prior studies. For the assessments of screening tools, sensitivity and NPV are the most important indicators [37]. If the best cut-off points for G8 and fTRST that were recommended by our study are used (G8 ≤13; fTRST ≥2), both the sensitivity (68.4% vs 65.5%) and the NPV (76.8% vs 74.2%) of G8 are higher than those of fTRST. Furthermore, the C-index of G8 is also significantly higher than that of fTRST. Therefore, compared with fTRST, G8 is more suitable for patients with cancer in Taiwan. The reason for the differences in the two screening tools may be because G8 was developed based on the Mini Nutritional Assessment

Table 4 The Effect of ECOG on G8 and fTRST (Construct Validity) (N = 755).

| Predictor | G8 | fTRST | Unstandardized coefficient | β | SE | Lower limit | Upper limit | p |
|-----------|----|-------|-----------------------------|---|----|-------------|------------|---|
| G8        |    |       | Score = 0a                  | – |    |             |            |   |
|           | F  |       |                             | –1.61 | 0.21 | –2.02 | –1.20 | 0.000 |
|           | Adjusted R² | 11.78*** |                       | 0.20 |    |             |            |   |
|           | ΔF | 59.55*** |                       | 0.06 |    |             |            |   |
| fTRST     |    |       | Score = 0a                  | – |    |             |            |   |
|           | F  |       |                             | 0.40 | 0.10 | 0.22 | 0.59 | 0.000 |
|           | Adjusted R² | 5.02*** |                       | 0.08 |    |             |            |   |
|           | ΔF | 17.94*** |                       | 0.02 |    |             |            |   |

***p < .001.
Adjust (G8): marital status, education, cancer type, cancer stage. Adjust (fTRST): gender, marital status, cancer type, comorbidity. a: reference group.
Abbreviation: SE: standard error.

Table 5 The Effect of Age on G8 and fTRST (Construct Validity) (N = 755).

| Predictor | G8 | fTRST | Unstandardized coefficient | β | SE | Lower limit | Upper limit | p |
|-----------|----|-------|-----------------------------|---|----|-------------|------------|---|
| G8        |    |       | Non-elderlya                | – |    |             |            |   |
|           | Elderly | 0.00 |                             | 0.35 | –0.68 | 0.68 | 0.999 |
|           | F  | 11.78*** |                       | 0.20 |    |             |            |   |
|           | ΔF | 0.00 |                       | 0.00 |    |             |            |   |
|           | ΔR² | 0.00 |                       | 0.00 |    |             |            |   |
| fTRST     |    |       | Non-elderlya                | – |    |             |            |   |
|           | Elderly | 0.14 |                             | 0.16 | –0.18 | 0.46 | 0.397 |
|           | F  | 5.02*** |                       | 0.08 |    |             |            |   |
|           | ΔF | 0.72 |                       | 0.00 |    |             |            |   |
|           | ΔR² | 0.00 |                       | 0.00 |    |             |            |   |

***p < .001.
Adjust (G8): marital status, education, cancer type, cancer stage, ECOG. Adjust (fTRST): gender, marital status, cancer type, ECOG, comorbidity. a: reference group.
Abbreviation: SE: standard error.
and 50.3% of the participants in our study had head and neck cancer and more likely had a malnourished status. However, G8 was originally designed for elderly patients with cancer. To expand the use of G8 to non-elderly populations, we advise for the scoring standards of some of the items to be modified. Taking item 8 for example, the score of both patients’ <65 years of age and patients 65–79 years of age was 2, and as such, it was impossible to distinguish the impact of age from this data. According to our results, we found that the frequencies of patients with cancer who are 40–64 years of age are 41.3%, while that of patients who are 65–74 years of age is 36.8%. Therefore, we suggest patient ages to be divided into <65 and ≥ 65 years cohorts, to distinguish the impact of age on frailty.

Our study found that both G8 and fTRST were significantly correlated with CGA, which supports the convergent validity of G8 and fTRST. Our study also verified the construct validity of G8 and fTRST, through comparing different ECOG scores (ECOG = 0 vs ≥ 1). Our result showed that patients with higher ECOG scores were more likely to be screened for frailty risk profiles using the G8 and fTRST, which supported the construct validity of G8 and fTRST. This result is also consistent with that of other past studies, which have found that the poorer the physical functional status of patients, the higher the associated frailty level [7, 35, 40]. Unfortunately, most of the studies on frailty have primarily analyzed the diagnostic characteristics of screening tools, and although the diagnostic characteristic of screening tools is important, testing their construct validity is also extremely important [41]. Therefore, we advise for future studies to include a validity test, while assessing the effectiveness of frailty screening tools, to better complete the assessment of screening tools.

Moreover, prior studies have also indicated that the prevalence of frailty increases with age [19, 20, 35]; however, the results of our study showed that age did not have a significant influence on G8 and fTRST. Such differences might be caused by the sample populations that had been enrolled in different studies. Previous studies had not concurrently analyzed frailty in both elderly and non-elderly patients with cancer. Only two studies have analyzed the prevalence of frailty in healthy populations, which included both elderly and non-elderly patients, and found that the prevalence of frailty increased with age [19, 20]. However, frailty in patients with cancer is affected by more complicated factors than those in healthy populations; in the elderly population, age is a factor that affects frailty. In patients with cancer, the main cause of frailty is the decline of multiple physiological systems, caused by disease [5, 6]. Although the construct validity of G8 and fTRST could not be verified in patients of different ages, our results revealed a critical message: age is an important factor; however, it may not be the only factor for distinguishing frailty in patients with cancer. Past studies have never investigated this issue, which reflects that it is necessary to screen frailty in non-elderly patients with cancer and conduct more studies to confirm our findings.

Our study has some limitations that merit further discussion. First, our study utilized CGA as the tool to identify the frailty of all adult patients with cancer. The CGA was developed for frailty assessment in geriatric populations, and some dimensions, such as number of falls, included in CGA may not be applicable in younger individuals. However, no comprehensive measurement tool for frailty assessment has been developed in non-elderly population till date and the aspects and instruments of frailty assessment in non-elderly patients with cancer are still debated and not validated [42]. Our data highlights that frailty is a common symptom among patients with cancer in various age groups. Thus, we suggest that researchers in the future could develop a comprehensive measurement tool to assess frailty in the non-geriatric population through sound research. Second, past studies of frailty have mainly focused on elderly patients and have rarely focused on both elderly and non-elderly patients with cancer. Therefore, it is difficult to compare the results of our study with those of other relevant studies. However, it reflects an advantage of our study that will enable experts and scholars to understand the importance of frailty assessments in non-elderly patients with cancer. Moreover, the pre-treatment screening of frailty in patients with cancer can serve as reference for physicians to discuss treatment plans with patients [40]. We also advise future studies to test more frailty screening tools to determine which screening tools are most suitable for patients with cancer in Taiwan. Third, the higher proportion of patients with HNC with high risk for malnutrition might bring bias to frailty assessment. However, our study showed similar performance of G8 and fTRST between patients with and without HNC. This suggests that our study results represent both HNC and non-HNC groups. To avoid such concern of bias, we recommend that future studies should, on average, enroll patients with different cancer types to balance the number of study participants with different cancer types.

Conclusions

Frailty is common in both elderly and non-elderly patients with cancer, and it may cause severe adverse outcomes. Thus, we advise clinicians to use G8 or fTRST to routinely screen for frailty risk profiles in patients with cancer before the commencement of cancer treatment. For patients with cancer in Taiwan, G8 is superior to fTRST in frailty screening tool performance. Furthermore, the optimal cut-off point recommended by our study can serve as reference point for clinicians to assess frailty and assist in treatment-related decision-making.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare no conflicts of interest.
Acknowledgements

The authors would like to thank all members of the Chang Gung Memorial Hospital Cancer Center for their help in data collection. Special thanks to all patients who participated in this project.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bj.2021.03.002.

REFERENCES

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.

[2] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–66.

[3] Tan KY, Kawamura Y, Tokomitsu A, Tang T. Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized. Am J Surg 2012;204:139–43.

[4] Green P, Arnold SV, Cohen DJ, Kirtane AJ, Kodali SK, Brown DL, et al. Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). Am J Cardiol 2015;116:264–9.

[5] Clegg A, Young J, Illiffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2015;381:752–62. Erratum in: Lancet 2013;382:1228.

[6] Ethan CG, Bilan MA, Jani AB, Maithel SK, Olan K, Master VA. Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin 2017;67:362–77.

[7] Huisingh-Scheetz M, Walston J. How should older adults with cancer be evaluated for frailty? J Geriatr Oncol 2017;8:8–15.

[8] Kenig J, Zychiewicz B, Olszewsa U, Barczynski M, Nowak W. How should older adults with cancer be evaluated for frailty? J Clin Oncol 2014;32:19–26.

[9] Smets IH, Kempen GI, Janssen-Heijnen ML, Deckx L, Buntinx F, van den Akker M. Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. BMC Geriatr 2014;14:26.

[10] Soubeyran P, Bellera C, Goyard J, Heitz D, Cure H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PloS One 2014;9:e115060.

[11] Kehler DS, Ferguson T, Stammers AN, Bohm C, Arora RC, Duhamel TA, et al. Prevalence of frailty in Canadians 18–79 years old in the Canadian health measures survey. BMC Geriatr 2017;17:28.

[12] Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ 2011;183:E487–94.

[13] Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23:2166–72.

[14] Meldon SW, Mion LC, Palmer RM, Drew BL, Connor JT, Lewicki JJ, et al. A brief risk stratification tool to predict repeat emergency department visits and hospitalizations in older patients discharged from the emergency department. Acad Emerg Med 2003;10:224–32.

[15] Kenis C, Geeraets A, Braes T, Milisen K, Flamaing J, Wildiers H. The Flemish version of the Triage Risk Screening Tool (TRST): a multidimensional short screening tool for the assessment of elderly patients. Crit Rev Oncol Hematol 2006;60:531.

[16] Lee JS, Schwindt G, Langevin M, Moghabghab R, Alibhai SM, Kias A, et al. Validation of the triage risk stratification tool to identify older persons at risk for hospital admission and returning to the emergency department. J Am Geriatr Soc 2008;56:2112–7.

[17] Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012;13:e437–44.

[18] Handforth C, Clegg A, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091–101.

[19] Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965;14:61–5.

[20] Lawton MP, Brody EM. Assessment of old people: self-maintaining and instrumental activities of daily living. Gerontol 1969;9:179–86.

[21] Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing multicentric study of 364 patients under chemotherapy. J Clin Oncol 2007;25:9040.

[22] Husty FM, Mion LC, Connor JT, Emerman CL, Campbell J, Palmer RM. A brief risk stratification tool to predict functional decline in older adults discharged from emergency departments. J Am Geriatr Soc 2007;55:1269–74.

[23] Overcash JA, Beckstead J, Moody L, Extermann M, Cobb S. The abbreviated comprehensive geriatric assessment (aCGA) for use in the older cancer patient as a prescreening tool: scoring and interpretation. Crit Rev Oncol Hematol 2006;59:205–10.

[24] Kenig J, Zychiewicz B, Olszewsa U, Richter P. Screening for frailty among older patients with cancer that qualify for abdominal surgery. J Geriatr Oncol 2015;6:52–9.

[25] Kamich J, Decoster L, Van Puyvelde K, De Greve J, Conings G, Milisen K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 2014;32:19–26.
the short-form mini-nutritional assessment (MNA-SF). J
Gerontol A Biol Sci Med Sci 2001;56:M366–72.
[30] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B,
Luthi JC, et al. Coding algorithms for defining comorbidities
in ICD-9-CM and ICD-10 administrative data. Med Care
2005;43:1130–9.
[31] Owusu C, Berger NA. Comprehensive geriatric assessment in
the older cancer patient: coming of age in clinical cancer
care. Clin Pract (Lond) 2014;11:749–62.
[32] Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF.
Youden Index and optimal cut-point estimated from
observations affected by a lower limit of detection. Biom J
2008;50:419–30.
[33] Bamber D. The area above the ordinal dominance graph and
the area below the receiver operating characteristic graph. J
Math Psychol 1975;12:387–415.
[34] Baesens B. Analytics in a big data world: the essential guide
to data science and its applications. New York: John Wiley &
Sons; 2014.
[35] Shamliyan T, Talley KM, Ramakrishnan R, Kane RL.
Association of frailty with survival: a systematic literature
review. Ageing Res Rev 2013;12:719–36.
[36] Perna S, Francis MDA, Bologna C, Moncaglieri F, Riva A,
Morazzoni P, et al. Performance of Edmonton Frail Scale on
frailty assessment: its association with multi-dimensional
geriatric conditions assessed with specific screening tools.
BMC Geriatr 2017;17:2.
[37] Baitar A, Van Fraeyenhove F, Vandbroek A, De Droogh E,
Gelderms D, Mebis J, et al. Geriatric screening results
and the association with severe treatment toxicity after the
first cycle of (radio)chemotherapy. J Geriatr Oncol
2014;5:179–84.
[38] Kenis C, Schuermans H, Van Cutsem E, Verhoef G,
Vansteenkiste J, Vergote I, et al. P8 Screening for a geriatric
risk profile in older cancer patients: a comparative study of
the predictive validity of three screening tools. Crit Rev Oncol
Hematol 2009;72:S22.
[39] Pottel L, Boterberg T, Pottel H, Goethals I, Van Den
Noortgat N, Duprez F, et al. Determination of an adequate
screening tool for identification of vulnerable elderly head
and neck cancer patients treated with radio (chemo) therapy.
J Geriatr Oncol 2012;3:24–32.
[40] Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-
Heijnen ML, Extermann M, et al. International Society of
Geriatric Oncology consensus on geriatric assessment in
older patients with cancer. J Clin Oncol 2014;32:2595–603.
[41] Bolarinwa OA. Principles and methods of validity and
reliability testing of questionnaires used in social and health
science researches. Niger Postgrad Med J 2015;22:195–201.
[42] Dharmarajan KV, Mohile SG. Can geriatric assessment
measures be used to determine cancer treatment
vulnerability in nongeriatric patients? Int J Radiat Oncol Biol
Phys 2020;108:612–4.